PhD Title: Mode of Action of Novel Anti-tubercular Drug¬s
BSc (Hons) Medical Biochemistry
Degree in Medical Biochemistry (B.Sc Hons.) from the University of Birmingham (July 2010)
The use of high-throughput screening (HTS) techniques to identify novel inhibitors of the causative agent of TB, Mycobacterium tuberculosis. Following the identification of potent inhibitors of M. tb, our aim is to establish the mechanism of action of the drugs. We do this following a multi-directional approach incorporating chemical proteomics and whole cell phenotypic methods. Identification of the mode of action (MOA) of inhibitors provides a foundation upon which to optimize the design and potency of drugs and therefore improve our capability to treat the emerging ‘superbug’ strains of M. tb. In 2012, 1.3 million people worldwide died due to TB infection and 450,000 people presented with multi-drug resistant TB (MDR-TB), with infections resistant to the ‘first-line’ antibiotics routinely used to treat a TB infection. The battle to combat drug resistance requires revolutionary thinking; a change in strategy from the classical target-driven approach to a top-down HTS campaign is simply the first step.
Abrahams KA*, Cox JAG*, Spivey VL, Loman NJ, Pallen MJ, et al. (2012) Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB. PLoS ONE 7(12): e52951. doi:10.1371/journal.pone.0052951
*These authors contributed equally to this work